SCHEMBL22658100

SCHEMBL22658100

CCOC(=O)c1oc(-c2ccc(O)cc2)nc1C

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 4/20 0.58
ESR1 P03372 3/20 0.58
ALDH1A1 P00352 2/20 0.57
LMNA P02545 1/20 0.57
TARBP2 Q15633 6/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
PDCD4 Q53EL6 1/20 0.50
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 3/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10709187 0.87 ALDH1A1 (0.75) ESR2ESR1ALDH1A1LMNATARBP2
SCHEMBL23574516 0.87 TARBP2 (0.67) ESR2ESR1ALDH1A1LMNATARBP2
SCHEMBL11622665 0.87 TARBP2 (0.63) ALDH1A1LMNATARBP2KDM4EHSD17B10
SCHEMBL3536215 0.86 TARBP2 (0.68) ALDH1A1LMNATARBP2PDCD4KDM4E
SCHEMBL3772666 0.84 MAPT (0.55) ALDH1A1LMNATARBP2PDCD4KDM4E
SCHEMBL6218840 0.84 ALDH1A1 (0.52) ESR2ESR1ALDH1A1LMNATARBP2
SCHEMBL22658109 0.83 TARBP2 (0.51) ESR2ESR1ALDH1A1LMNATARBP2
SCHEMBL22658069 0.82 TARBP2 (0.48) ESR2ESR1ALDH1A1LMNATARBP2
SCHEMBL15049287 0.80 TARBP2 (0.64) ESR2ESR1ALDH1A1LMNATARBP2
SCHEMBL7907774 0.80 TARBP2 (0.82) ESR2ESR1ALDH1A1TARBP2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO INC (US) 2026-03-26 US disclosed
US-12441689-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2025-10-14 US disclosed
US-20230084752-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-03-16 US disclosed
EP-3969439-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF Metabomed Ltd (IL) 2022-03-23 EP disclosed
CN-114127049-A ACSS2 inhibitors and methods of use thereof 美特波米德有限公司 2022-03-01 CN disclosed
WO-2020230134-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2020-11-19 WO disclosed
WO-2020230134-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2020-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230084752-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 ESR2 3155/4885ESR1 3472/4885ALDH1A1 347/4885
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ACSL3 ESR2 2488/4885ESR1 3810/4885ALDH1A1 1031/4885
US-12441689-B2 ACSS2 inhibitors and methods of use thereof ACSS2, ADSS2, GLS2 ESR2 3155/4885ESR1 3472/4885ALDH1A1 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.